Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH)

2018 ◽  
Vol 32 (3) ◽  
pp. 179-185 ◽  
Author(s):  
Marta González-Vicent ◽  
Jaime Sanz ◽  
José Luis Fuster ◽  
Joan Cid ◽  
Cristina Díaz de Heredia ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Retrospective Analysis ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Hematopoietic Stem

scholarly journals Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation

2018 ◽  
Vol 2 (19) ◽  
pp. 2550-2553 ◽  
Author(s):  
Catharina Schuetz ◽  
Manfred Hoenig ◽  
Despina Moshous ◽  
Christof Weinstock ◽  
Martin Castelle ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Rescue Therapy ◽  
Hematopoietic Stem ◽  
Life Threatening

Abstract New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post–hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.

Sign in / Sign up

Export Citation Format

Share Document